Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,764,782
  • Shares Outstanding, K 166,441
  • Annual Sales, $ 2,826 M
  • Annual Income, $ 311,000 K
  • 60-Month Beta 0.46
  • Price/Sales 3.09
  • Price/Cash Flow 15.98
  • Price/Book 3.44
Trade RDY with:

Options Overview Details

View History
  • Implied Volatility 39.66% ( -0.24%)
  • Historical Volatility 23.01%
  • IV Percentile 68%
  • IV Rank 54.36%
  • IV High 56.31% on 03/14/22
  • IV Low 19.84% on 08/10/21
  • Put/Call Vol Ratio 0.25
  • Today's Volume 5
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 182
  • Open Int (30-Day) 175

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.60
  • Number of Estimates 1
  • High Estimate 0.60
  • Low Estimate 0.60
  • Prior Year 0.80
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.00 +4.25%
on 07/29/22
57.58 -7.66%
on 07/15/22
-2.47 (-4.44%)
since 07/08/22
3-Month
49.59 +7.22%
on 05/12/22
57.58 -7.66%
on 07/15/22
+2.31 (+4.54%)
since 05/06/22
52-Week
47.88 +11.05%
on 03/07/22
67.76 -21.53%
on 09/15/21
-11.20 (-17.40%)
since 08/06/21

Most Recent Stories

More News
Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

RDY : 53.17 (+0.97%)
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.

RDY : 53.17 (+0.97%)
BEAM : 63.69 (+0.41%)
ATRA : 3.63 (+5.52%)
DTIL : 1.6100 (-7.47%)
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into...

RDY : 53.17 (+0.97%)
Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Bortezomib...

RDY : 53.17 (+0.97%)
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch...

RDY : 53.17 (+0.97%)
Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announces the launch of Dr. Reddy’s Fesoterodine...

RDY : 53.17 (+0.97%)
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory...

RDY : 53.17 (+0.97%)
Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has acquired a...

RDY : 53.17 (+0.97%)
ETON : 2.98 (+1.36%)
Eton Pharmaceuticals Announces Sale of Hospital Products

Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 millionGoing forward, Eton’s commercial...

ETON : 2.98 (+1.36%)
RDY : 53.17 (+0.97%)
Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s...

RDY : 53.17 (+0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through...

See More

Key Turning Points

3rd Resistance Point 53.78
2nd Resistance Point 53.52
1st Resistance Point 53.35
Last Price 53.17
1st Support Level 52.92
2nd Support Level 52.66
3rd Support Level 52.49

See More

52-Week High 67.76
Fibonacci 61.8% 60.17
Fibonacci 50% 57.82
Fibonacci 38.2% 55.47
Last Price 53.17
52-Week Low 47.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar